- Markets
- Trading
- TRIMURTHI
TRIMURTHI
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Novelix Pharma do?
Trimurthi Limited, a Public Limited Company based in Hyderabad, Telangana, is engaged in trading pharmaceuticals, related products, shares, and securities.
Who are the competitors of Novelix Pharma?
Novelix Pharma major competitors are Sattva Sukun Lifecar, Dhyaani Tradeventtur, Sinnar Bidi Udyog, Mihika Industries, Ecofinity Atomix, MRC Agrotech, Adhata Global. Market Cap of Novelix Pharma is ₹26 Crs. While the median market cap of its peers are ₹25 Crs.
Is Novelix Pharma financially stable compared to its competitors?
Novelix Pharma seems to be less financially stable compared to its competitors. Altman Z score of Novelix Pharma is -396.36 and is ranked 8 out of its 8 competitors.
Does Novelix Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Novelix Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Novelix Pharma allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Novelix Pharma balance sheet?
Novelix Pharma balance sheet is weak and might have solvency issues
Is the profitablity of Novelix Pharma improving?
Yes, profit is increasing. The profit of Novelix Pharma is ₹0.16 Crs for Mar 2024, -₹0.05 Crs for Mar 2023 and -₹1.56 Crs for Mar 2022
Is the debt of Novelix Pharma increasing or decreasing?
Yes, The debt of Novelix Pharma is increasing. Latest debt of Novelix Pharma is -₹0.22 Crs as of Mar-24. This is greater than Mar-23 when it was -₹0.49 Crs.
Is Novelix Pharma stock expensive?
Yes, Novelix Pharma is expensive. Latest PE of Novelix Pharma is 130, while 3 year average PE is 22.68. Also latest EV/EBITDA of Novelix Pharma is 339 while 3yr average is 7.65.
Has the share price of Novelix Pharma grown faster than its competition?
Novelix Pharma has given better returns compared to its competitors. Novelix Pharma has grown at ~42.22% over the last 3yrs while peers have grown at a median rate of 1.0%
Is the promoter bullish about Novelix Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Novelix Pharma is 66.56% and last quarter promoter holding is 66.56%.
Are mutual funds buying/selling Novelix Pharma?
There is Insufficient data to gauge this.